Filing Details
- Accession Number:
- 0001209191-21-012328
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-19 16:08:37
- Reporting Period:
- 2021-02-17
- Accepted Time:
- 2021-02-19 16:08:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-02-17 | 6,240 | $211.75 | 55,460 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2021-02-18 | 1,022 | $210.05 | 54,438 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-18 | 3,940 | $211.77 | 50,498 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-18 | 2,763 | $212.49 | 47,735 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-18 | 100 | $213.26 | 47,635 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $210.05 (range $209.63 to $210.52).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $211.77 (range $211.15 to $212.14).
- Open market sales reported on this line occurred at a weighted average price of $212.49 (range $212.15 to $213.04).
- Open market sales reported on this line occurred at a weighted average price of $213.26 (range $213.23 to $213.29).
Billionaire Hedge Funds
